Abstract
The development of resistance to anticancer agents during treatment is a major obstacle to successful cancer therapy [1–3]. In addition, certain tumor cells exhibit de novo resistance to anticancer agents. De novo resistance is commonly observed in renal, gastric, and colon cancers, and it precludes successful treatment of these diseases with chemotherapeutic drugs [2]. Cultured tumor cell populations often acquire a multidrug resistance (MDR) phenotype after prolonged exposure to cytotoxic natural products such as anthracyclines, vinca alkaloids, and epipodophyllotoxins [1–3]. MDR tumor cells are by definition resistant to the cytotoxic effects of the selecting agent and cross-resistant to cytotoxic natural products that are structurally diverse but generally have in common the ability to produce MDR tumor cells from drug-sensitive tumor cell populations [1-3]. Patterns of cross-resistance observed among different MDR tumor cell lines are variable and unpredictable. Because many of the cytotoxic natural products linked to the MDR phenotype are anticancer agents [1–3], it is believed that an understanding of the MDR phenotype could potentially lead to significant improvements in cancer theraphy [1].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Endicott, J.A. and Ling, V. 1989. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58: 137–171.
Tsuruo, T. 1988. Mechanisms of multidrug resistance and implications for therapy. Jpn. J. Cancer. Res. 79: 285–296.
Moscow, J.A. and Cowan, K.H. 1988. Multidrug resistance. J. Natl. Cancer Inst. 80: 14–20.
Fojo, A.T., Ueda, K., Slamon, D.J., Poplack, D.G., Gottesman, M.M., and Pastan, I. 1987. Expression of a multidrug-resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. 84: 265–269.
Goldstein, L.J., Galski, H., Fojo, A., Willingham, M., Lai, S.-L., Gazdar, A., Pirker, R., Green, A., Crist, W., Brodeur, G.M., Lieber, M., Cossman, J., Gottesman, M.M., and Pastan, I. 1989. Expression of a multidrug resistance gene in human cancers. J. Natl. Cancer Inst. 81: 116–124.
Bradley, G., Sharma, R., Rajalakshmi, S., and Ling, V. 1992. P-glycoprotein expression during tumor progression in the rat liver. Cancer Res. 52: 5154–5161.
Weinstein, R.S., Jakate, S.M., Dominguez, J.M., Lebovitz, M.D., Koukoulis, G.K., Kuszak, J.R., Klusens, L.F., Grogan, T.M., Saclarides, T.J., Roninson, I.B., and Coon, J.S. 1991. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 51: 2720–2726.
Chan, H.S.L., Thorner, P.S., Haddad, G., and Ling, V. 1990. Immunohistochemical detection of P-glycoprotein: Prognostic correlation in soft tissue sarcoma of childhood. J. Clin. Oncol. 8: 689–704.
O’Brian, C.A. and Ward, N.E. 1989. Biology of the protein kinase C family. Cancer Metastasis Rev. 8: 199–214.
Bell, R.M. and Burns, D.J. 1991. Lipid activation of protein kinase C. J. Biol. Chem. 266: 4661–4664.
O’Brian, CA., Fan, D., Ward, N.E., Seid, C., and Fidler, I.J. 1989. Level of protein kinase C activity correlates directly with resistance to Adriamycin in murine fibrosarcoma cells. FEBS Letts. 246: 78–82.
Fine, R.L., Patel, J., and Chabner, B.A. 1988. Phorbol esters induce multidrug resistance in human breast cancer cells. Proc. Natl. Acad. Sci. USA 85: 582–586.
Palayoor, S.T., Stein, J.M., and Hait, W.N. 1987. Inhibition of protein kinase C by antineoplastic agents: Implications for drug resistance. Biochem. Biophys. Res. Commun. 148: 718–725.
Posada, J.A., McKeegan, E.M., Worthington, K.F., Morin, M.J., Jaken, S., and Tritton, T.R. 1989. Human multidrug resistant KB cells overexpress protein kinase C: Involvement in drug resistance. Cancer Commun. 1: 285–292.
Aquino, A., Hartman, K.D., Knode, M.C., Grant, S., Huang, K.-P., Niu, C.-H., and Glazer, RI. 1988. Role of protein kinase C in phosphorylation of vinculin in Adriamycin-resistant HL-60 leukemia cells. Cancer Res. 48: 3324–3329.
Chambers, T.C., McAvoy, E.M., Jacobs, J.W., and Eilon, G. 1990. Protein kinase C phosphorylates P-glycoprotein in multidrug resistant human KB carcinoma cells. J. Biol. Chem. 265: 7679–7686.
Schwartz, G.K., Arkin, H., Holland, J.F., and Ohnuma, T. 1991. Protein kinase C activity and multidrug resistance in MOLT-3 human lymphoblastic leukemia cells resistant to trimetrexate. Cancer Res. 51: 55–61.
Ido, M., Sato, K., Sakurai, M., Inagaki, M., Saitoh, M., Watanabe, M., and Hidaka, H. 1987. Decreased phorbol ester receptor and protein kinase C in P388 murine leukemic cells resistant to etoposide. Cancer Res. 47: 3460–3463.
Ido, M., Asao, T., Sakurai, M., Inagaki, M., Saito, M., and Hidaka, H. 1986. An inhibitor of protein kinase C, l-(5-isoquinolinylsulfonyl)-2-methylpiperazine (H7) inhibits TPA-induced reduction of vincristine uptake from P388 murine leukemic cell. Leukemia Res. 10: 1063–1069.
Lee, S.A., Karaszkiewicz, J.W., and Anderson, W.B. 1992. Elevated level of nuclear protein kinase C in multidrug-resistant MCF-7 human breast carcinoma cells. Cancer Res. 52: 3750–3759.
Posada, J., Vichi, P., and Tritton, TR. 1989. Protein kinase C in Adriamycin action and resistance in mouse sarcoma 180 cells. Cancer Res. 49: 6634–6639.
O’Brian, CA., Fan, D., Ward, N.E., Dong, Z., Iwamoto, L., Gupta, K.P., Earnest, L.E., and Fidler, I.J. 1991. Transient enhancement of multidrug resistance by the bile acid deoxycholate in murine fibrosarcoma cells in vitro. Biochem. Pharmacol. 41: 797–806.
Ward, N.E. and O’Brian, C.A. 1991. Distinct patterns of phorbol ester-induced down-regulation of protein kinase C activity in Adriamycin-selected multidrug resistant and parental murine fibrosarcoma cells. Cancer Lett. 58: 189–193.
Blobe, G.C., Sachs, C.W., Khan, W.A., Fabbro, D., Stabel, S., Wetsel, W.C., Obeid, L.M., Fine, R.L., and Hannun, Y.A. 1993. Selective regulation of expression of protein kinase C (PKC) isoenzymes in multidrug-resistant MCF7 cells. J. Biol. Chem. 268: 658–664.
Aquino, A., Warren, B.S., Omichinski, J., Hartman, K.D., and Glazer, R.I. 1990. Protein kinase C-γ is present in Adriamycin-resistant HL-60 leukemia cells. Biochem. Biophys. Res. Commun. 166: 723–728.
Efferth, T. and Volm, M. 1992. Expression of protein kinase C in human renal cell carcinoma cells with inherent resistance to doxorubicin. Anticancer Res. 12: 2209–2212.
Chambers, T.C., Chalikonda, I., and Eilon, G. 1990. Correlation of protein kinase C trans-location, P-glycoprotein phosphorylation and reduced drug accumulation in multidrug resistant human KB cells. Biochem. Biophys. Res. Commun. 169: 253–259.
Dong, Z., Ward, N.E., Fan, D., Gupta, K.P., and O’Brian, C.A. 1991. In vitro model for intrinsic drug resistance: Effects of protein kinase C activators on the chemosensitivity of cultured human colon cancer cells. Mol. Pharmacol. 39: 563–569.
Ferguson, P.J. and Cheng, Y. 1987. Transient protection of cultured human cells against antitumor agents by 12-0-tetradecanoylphorbol-13-acetate. Cancer Res. 47: 433–441.
Nygren, P. and Larsson, R. 1990. Modulation of vincristine sensitivity of human kidney tumor cells by pharmacological agents interfering with intracellular signals. No apparent relationship to changes in cytoplasmic Ca2+ or pH. Biochim. Biophys. Acta 1052: 392–398.
Kessel, D. 1988. Effects of phorbol esters on doxorubicin transport systems. Biochem. Pharmacol. 37: 2297–2299.
Yu, G., Ahmad, S., Aquino, A., Fairchild, C.R., Trepel, J.B., Ohno, S., Suzuki, K., Tsuruo, T., Cowan, K.H., and Glazer, R.I. 1991. Transfection with protein kinase Cα confers increased multidrug resistance to MCF-7 cells expressing P-glycoprotein. Cancer Commun. 3: 181–189.
Fan, D., Fidler, I.J., Ward, N.E., Seid, C., Earnest, L.E., Housey, G.M., and O’Brian, C.A. 1992. Stable expression of a cDNA encoding rat brain protein kinase C-ß, confers a multidrug-resistant phenotype on rat fibroblasts. Anticancer Res. 12: 661–668.
Qian, X. and Beck, W.T. 1990. Binding of an optically pure photoaffinity analogue of verapamil, LU-49888, to P-glycoprotein from multidrug-resistant human leukemic cell lines. Cancer Res. 50: 1132–1137.
Yusa, K. and Tsuruo, T. 1989. Reversal mechanism of multidrug resistance by verapamil: Direct binding of verapamil to P-glycoprotein on specific sites and transport of verapamil outward across the plasma membrane of K562/ADM cells. Cancer Res. 49: 5002–5006.
Hidaka, H., Inagaki, M., Kawamoto, S., and Sasaki, Y., 1984. Isoquinolinesulfonamides, novel and potent inhibitors of cyclic nucleotide dependent protein kinase and protein kinase C. Biochemistry 23: 5036–5041.
O’Brian, CA., Ward, N.E., Liskamp, R.M., de Bont, D.B., Earnest, L.E., van Boom, J.H., and Fan, D. 1991. A novel, N-myristylated synthetic octapeptide inhibits protein kinase C activity and partially reverses murine fibrosarcoma cell resistance to Adriamycin. Invest. New Drugs 9: 169–179.
O’Brian, C.A. and Ward, N.E. 1990. Staurosporine: A prototype of a novel class of inhibitors of tumor cell invasion? J. Natl. Cancer Inst. 82: 1734–1735.
Mori, T., Takai, Y., Minakuchi, R., Yu, B., and Nishizuka, Y. 1980. Inhibitory action of chlorpromazine, dibucaine, and other phospholipid-interacting drugs on calcium-activated, phospholipid-dependent protein kinase. J. Biol. Chem. 255: 8378–8380.
Hagiwara, M., Wakusawa, S., Miyamoto, K.I., and Hidaka, H. 1991. Obviation of drug resistance and affinity purification of P-glycoprotein by isoquinolinesulfonamides. Cancer Lett. 60: 103–107.
Miyamoto, K.I., Inoko, K., Ikeda, K., Wakusawa, S., Kajita, S., Hasegawa, T., Takagi, K., and Koyama, M. 1993. Effect of staurosporine derivatives on protein kinase activity and vinblastine accumulation in mouse leukemia P388/ADR cells. J. Pharm. Pharmacol. 45: 43–47.
O’Brian, CA., Liskamp, R.M., Solomon, D.H., and Weinstein, I.B. 1985. Inhibition of protein kinase C by tamoxifen. Cancer Res. 45: 2462–2465.
Su, H.-D., Mazzei, G.J., Vogler, W.R., and Kuo, J.F. 1985. Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/calcium-dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary. Biochem. Pharmacol. 34: 3649–3653.
O’Brian, C.A., Ward, N.E., and Anderson, B.W. 1988. Role of specific interactions between protein kinase C and triphenylethylenes in inhibition of the enzyme. J. Natl. Cancer Inst. 80: 1628–1633.
Akiyama, S., Shiraishi, N., Kuratomi, Y., Nakagawa, M., and Kuwano, M. 1986. Circumvention of multiple-drug resistance in human cancer cells by thioridazine, trifluoperazine, and chlorpromazine. J. Natl. Cancer Inst. 76: 839–844.
Wise, B.C., Glass, D.B., Chou, C.H.J., Raynor, R.L., Katoh, N., Schatzman, R.C., Turner, R.S., Kibler, R.F., and Kuo, J.F. 1982. Phospholipid-sensitive Ca2+-dependent protein kinase from heart. J. Biol. Chem. 257: 8489–8495.
Hait, W.N. and Pierson, N.R. 1990. Comparison of the efficacy of a phenothiazine and a bisquinaldinium calmodulin antagonist against multidrug-resistant P388 cell lines. Cancer Res. 50: 1165–1169.
Weisenthal, L.M., Su, Y.-Z., Duarte, T.E., Dill, P.L., and Nagourney, R.A. 1987. Perturbation of in vitro drug resistance in human lymphatic neoplasms by combinations of putative inhibitors of protein kinase C. Cancer Treat. Rep. 71: 1239–1243.
Chatterjee, M. and Harris, A.L. 1990. Reversal of acquired resistance to Adriamycin in CHO cells by tamoxifen and 4-hydroxy tamoxifen: Role of drug interaction with alpha 1 acid glycoprotein. Br. J. Cancer 62: 712–717.
Mellado, W. and Horwitz, S.B. 1987. Phosphorylation of the multidrug resistance associated glycoprotein. Biochemistry 26: 6900–6904.
Staats, J., Marquardt, D., and Center, M.S. 1990. Characterization of a membrane-associated protein kinase of multidrug-resistant HL60 cells which phosphorylates P-glycoprotein. J. Biol. Chem. 265: 4084–4090.
Hamada, H. and Tsuruo, T. 1988. Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 48: 4926–4932.
Safa, A.R., Glover, C.J., Meyers, M.B., Biedler, J.L., and Felsted, R.L. 1986. Vinblastine photoaffinity labeling of a high molecular weight surface membrane glycoprotein specific for multidrug-resistant cells. J. Biol. Chem. 261: 6137–6140.
Hamada, H., Hagiwara, K.-I., Nakajima, T., and Tsuruo, T. 1987. Phosphorylation of the Mr 170,000 to 180,000 glycoprotein specific to multidrug-resistant tumor cells: Effects of verapamil, trifluoperazine, and phorbol esters. Cancer Res. 47: 2860–2865.
Chambers, T.C., Pohl, J., Raynor, R.L., and Kuo, J.F. 1993. Identification of specific sites in human P-glycoprotein phosphorylated by protein kinase C. J. Biol. Chem. 268: 4592–4595.
Werth, D.K., Niedel, J.E., and Pastan, I. 1983. Vinculin, a cytoskeletal substrate of protein kinase C. J. Biol. Chem. 258: 11423–11426.
Epand, R.M. and Stafford, A.R. 1993. Protein kinases and multidrug resistance. Cancer J. 6: 154–157.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
O’Brian, C.A., Ward, N.E., Gravitt, K.R., Fan, D. (1994). The role of protein kinase C in multidrug resistance. In: Goldstein, L.J., Ozols, R.F. (eds) Anticancer Drug Resistance. Cancer Treatment and Research, vol 73. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-2632-2_3
Download citation
DOI: https://doi.org/10.1007/978-1-4615-2632-2_3
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6129-9
Online ISBN: 978-1-4615-2632-2
eBook Packages: Springer Book Archive